Chemistry

SnoopLigase peptide-peptide conjugation allows modular vaccine meeting


1.

Lipsitch, M. & O’Hagan, J. J. Patterns of antigenic variety and the mechanisms that keep them. J. R. Soc. Interface four, 787–802 (2007).

2.

Dormitzer, P. R., Grandi, G. & Rappuoli, R. Structural vaccinology begins to ship. Nat. Rev. Microbiol. 10, 807–813 (2012).

three.

Burton, D. R. & Hangartner, L. Broadly Neutralizing Antibodies to HIV and Their Function in Vaccine Design. Annu. Rev. Immunol. 34, 635–659 (2016).

four.

Chen, L. et al. An EGF-like Protein Kinds a Advanced with PfRh5 and Is Required for Invasion of Human Erythrocytes by Plasmodium falciparum. PLoS Pathog. 7, e1002199 (2011).

5.

Draper, S. J. et al. Malaria Vaccines: Current Advances and New Horizons. Cell Host Microbe 24, 43–56 (2018).

6.

Vaughan, A. M. & Kappe, S. H. I. Malaria vaccine growth: persistent challenges. Curr. Opin. Immunol. 24, 324–331 (2012).

7.

Estívariz, C. F. et al. Poliovirus vaccination choices for attaining eradication and securing the endgame. Curr. Opin. Virol. three, 309–315 (2013).

eight.

Poland, J. D., Calisher, C. H., Monath, T. P., Downs, W. G. & Murphy, Okay. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. World Well being Organ. 59, 895–900 (1981).

9.

Lievano, F. et al. Measles, mumps, and rubella virus vaccine (M-M-RTMII): a assessment of 32 years of medical and postmarketing expertise. Vaccine 30, 6918–26 (2012).

10.

Schiller, J. & Lowy, D. Explanations for the excessive efficiency of HPV prophylactic vaccines. Vaccine 36, 4768–4773 (2018).

11.

Sankaranarayanan, R. et al. Immunogenicity and HPV an infection after one, two, and three doses of quadrivalent HPV vaccine in ladies in India: a multicentre potential cohort research. Lancet Oncol. 17, 67–77 (2016).

12.

Kreimer, A. R. et al. Proof for single-dose safety by the bivalent HPV vaccine—Overview of the Costa Rica HPV vaccine trial and future analysis research. Vaccine 36, 4774–4782 (2018).

13.

Brune, Okay. D. et al. Plug-and-Show: ornament of Virus-Like Particles through isopeptide bonds for modular immunization. Sci. Rep. 6, 19234 (2016).

14.

Brune, Okay. D. et al. Twin Plug-and-Show Artificial Meeting Utilizing Orthogonal Reactive Proteins for Twin Antigen Immunization. Bioconjug. Chem. 28, 1544–1551 (2017).

15.

Thrane, S. et al. Bacterial superglue allows straightforward growth of environment friendly virus-like particle based mostly vaccines. J. Nanobiotechnology 14, 30 (2016).

16.

Jegerlehner, A. et al. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. European Journal of Immunology 32, 3305–3314 (2002).

17.

Bachmann, M. F. et al. The affect of antigen group on B cell responsiveness. Science 262, 1448–51 (1993).

18.

De Silva, N. S. & Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137–148 (2015).

19.

Bachmann, M. F. & Jennings, G. T. Vaccine supply: A matter of measurement, geometry, kinetics and molecular patterns. Nature Critiques Immunology 10, 787–796 (2010).

20.

Andersson, A.-M. C. et al. Elevated Immunogenicity and Protecting Efficacy of Influenza M2e Fused to a Tetramerizing Protein. PLoS One 7, e46395 (2012).

21.

Taylor, D. N. et al. Improvement of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved security and immune response. Vaccine 30, 5761–5769 (2012).

22.

Turley, C. B. et al. Security and immunogenicity of a recombinant M2e–flagellin influenza vaccine (STF2.4xM2e) in wholesome adults. Vaccine 29, 5145–5152 (2011).

23.

Ogun, S. A., Dumon-Seignovert, L., Marchand, J.-B., Holder, A. A. & Hill, F. The Oligomerization Area of C4-Binding Protein (C4bp) Acts as an Adjuvant, and the Fusion Protein Comprised of the 19-Kilodalton Merozoite Floor Protein 1 Fused with the Murine C4bp Area Protects Mice in opposition to Malaria. Infect. Immun. 76, 3817–3823 (2008).

24.

Leneghan, D. B. et al. Nanoassembly routes stimulate conflicting antibody amount and high quality for transmission-blocking malaria vaccines. Scientific Stories 7, 3811 (2017).

25.

Li, Y. et al. Enhancing immunogenicity and transmission-blocking exercise of malaria vaccines by fusing Pfs25 to IMX313 multimerization expertise. Scientific Stories 6, 18848 (2016).

26.

Menon, V. et al. Evaluation of Antibodies Induced by Multivalent Transmission-Blocking Malaria Vaccines. Entrance. Immunol. eight, 1998 (2017).

27.

Patterson, D. P., Rynda-Apple, A., Harmsen, A. L., Harmsen, A. G. & Douglas, T. Biomimetic Antigenic Nanoparticles Elicit Managed Protecting Immune Response to Influenza. ACS Nano 7, 3036–3044 (2013).

28.

Georgiev, I. S. et al. Two-Element Ferritin Nanoparticles for Multimerization of Various Trimeric Antigens. ACS Infect. Dis. four, 788–796 (2018).

29.

Zhai, Y., Zhong, Z., Zariffard, M., Spear, G. T. & Qiao, L. Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal exterior area of HIV-1 gp41 induced mucosal and systemic antibodies. Vaccine 31, 5422–5429 (2013).

30.

Chackerian, B. Virus-like particles: versatile platforms for vaccine growth. Skilled Rev. Vaccines 6, 381–390 (2007).

31.

Brune, Okay. D. & Howarth, M. Routes and Alternatives for Modular Building of Particulate Vaccines: Stick, Click on, and Glue. Entrance. Immunol. 9, 1432 (2018).

32.

Patel, Okay. G. & Swartz, J. R. Floor Functionalization of Virus-Like Particles by Direct Conjugation Utilizing Azide−Alkyne Click on Chemistry. Bioconjug. Chem. 22, 376–387 (2011).

33.

Tang, S., Xuan, B., Ye, X., Huang, Z. & Qian, Z. A Modular Vaccine Improvement Platform Based mostly on Sortase-Mediated Web site-Particular Tagging of Antigens onto Virus-Like Particles. Sci. Rep. 6, 25741 (2016).

34.

Thérien, A. et al. A flexible papaya mosaic virus (PapMV) vaccine platform based mostly on sortase-mediated antigen coupling. J. Nanobiotechnology 15, 54 (2017).

35.

Thrane, S. et al. A Novel Virus-Like Particle Based mostly Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA. PLoS One 10, e0143071 (2015).

36.

Akhras, S. et al. Cell-permeable capsids as common antigen service for the induction of an antigen-specific CD8+ T-cell response. Sci. Rep. 7, 9630 (2017).

37.

Koho, T. et al. His-tagged norovirus-like particles: A flexible platform for mobile supply and floor show. Eur. J. Pharm. Biopharm. 96, 22–31 (2015).

38.

Low, J. G. H. et al. Security and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Outcomes from a double-blinded, randomized Part I medical trial in wholesome Asian volunteers. Vaccine 32, 5041–5048 (2014).

39.

Scaria, P. V. et al. Protein-protein conjugate nanoparticles for malaria antigen supply and enhanced immunogenicity. PLoS One 12, e0190312 (2017).

40.

Buldun, C. M., Jean, J. X., Bedford, M. R. & Howarth, M. SnoopLigase Catalyzes Peptide–Peptide Locking and Allows Stable-Part Conjugate Isolation. J. Am. Chem. Soc. 140, 3008–3018 (2018).

41.

Brune, Okay. D. et al. Twin Plug-and-Show Artificial Meeting Utilizing Orthogonal Reactive Proteins for Twin Antigen Immunization. Bioconjugate Chemistry 28, 1544–1551 (2017).

42.

Jin, J. et al. Accelerating the medical growth of protein-based vaccines for malaria by environment friendly purification utilizing a 4 amino acid C-terminal ‘C-tag’. Worldwide Journal for Parasitology 47, 435–446 (2017).

43.

Baruch, D. I. et al. Identification of a area of PfEMP1 that mediates adherence of Plasmodium falciparum contaminated erythrocytes to CD36: conserved perform with variant sequence. Blood 90, 3766–75 (1997).

44.

Turner, L. et al. Extreme malaria is related to parasite binding to endothelial protein C receptor. Nature 498, 502–505 (2013).

45.

Volz, J. C. et al. Important Function of the PfRh5/PfRipr/CyRPA Advanced throughout Plasmodium falciparum Invasion of Erythrocytes. Cell Host Microbe 20, 60–71 (2016).

46.

Manske, M. et al. Evaluation of Plasmodium falciparum variety in pure infections by deep sequencing. Nature 487, 375–379 (2012).

47.

Favuzza, P. et al. Technology of Plasmodium falciparum parasite-inhibitory antibodies by immunization with recombinantly-expressed CyRPA. Malar. J. 15, 161 (2016).

48.

Bethune, M. T. & Joglekar, A. V. Personalised T cell-mediated most cancers immunotherapy: progress and challenges. Curr. Opin. Biotechnol. 48, 142–152 (2017).

49.

Kokhaei, P. et al. Telomerase (hTERT 611–626) serves as a tumor antigen in B-cell persistent lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp. Hematol. 35, 297–304 (2007).

50.

Ott, G., Radhakrishnan, R., Fang, J.-H. & Hora, M. The Adjuvant MF59: A 10-Yr Perspective. in Vaccine Adjuvants (ed. O’Hagan, D. T.) 211–228 (Humana Press). https://doi.org/10.1385/1-59259-Zero83-7:211 (2000).

51.

Medical Trials Partnership, S. Efficacy and security of RTS,S/AS01 malaria vaccine with or with no booster dose in infants and kids in Africa: remaining outcomes of a part three, individually randomised, managed trial. Lancet 386, 31–45 (2015).

52.

Klein, S. L., Shann, F., Moss, W. J., Benn, C. S. & Aaby, P. RTS,S Malaria Vaccine and Elevated Mortality in Ladies. MBio 7, e00514–16 (2016).

53.

Regules, J. A. et al. Fractional Third and Fourth Dose of RTS, S/AS01 Malaria Candidate Vaccine: A Part 2a Managed Human Malaria Parasite An infection and Immunogenicity Research. J. Infect. Dis. 214, 762–771 (2016).

54.

McHugh, Okay. J., Guarecuco, R., Langer, R. & Jaklenec, A. Single-injection vaccines: Progress, challenges, and alternatives. J. Management. Launch 219, 596–609 (2015).

55.

Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J. & Howarth, M. Engineering a Rugged Nanoscaffold to Improve Plug-and-Show Vaccination. ACS Nano 12, 8855–8866 (2018).

56.

Plebanski, M. et al. Financial and sensible challenges to the formulation of vaccines in opposition to endemic infectious ailments corresponding to malaria. Strategies 40, 77–85 (2006).

57.

Veggiani, G., Zakeri, B. & Howarth, M. Superglue from micro organism: Unbreakable bridges for protein nanotechnology. Developments in Biotechnology 32, 506–512 (2014).

58.

Beaumont, E. & Roingeard, P. Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce environment friendly anti-HCV antibody manufacturing in animals pre-immunized with HBV vaccine. Vaccine 33, 973–976 (2015).

59.

Chackerian, B., Lenz, P., Lowy, D. R. & Schiller, J. T. Determinants of Autoantibody Induction by Conjugated Papillomavirus Virus-Like Particles. J. Immunol. 169, 6120–6126 (2002).

60.

Chuan, Y. P. et al. Results of pre-existing anti-carrier immunity and antigenic aspect multiplicity on efficacy of a modular virus-like particle vaccine. Biotechnol. Bioeng. 110, 2343–2351 (2013).

61.

Jegerlehner, A. et al. Provider induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon attributable to carrier-specific antibodies. Vaccine 28, 5503–5512 (2010).

62.

Desrichard, A., Snyder, A. & Chan, T. A. Most cancers Neoantigens and Purposes for Immunotherapy. Clin. Most cancers Res. 22, 807–812 (2016).

63.

Palladini, A. et al. Virus-like particle show of HER2 induces potent anti-cancer responses. Oncoimmunology 7, e1408749 (2018).

64.

Singh, S. Okay. et al. Enhancing the malaria transmission-blocking exercise of a Plasmodium falciparum 48/45 based mostly vaccine antigen by SpyTag/SpyCatcher mediated virus-like show. Vaccine 35, 3726–3732 (2017).

65.

Janitzek, C. M. et al. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine able to inducing excessive and sturdy antibody responses. Malar. J. 15, 545 (2016).

66.

Kasaraneni, N., Chamoun-Emanuelli, A. M., Wright, G. & Chen, Z. Retargeting Lentiviruses through SpyCatcher-SpyTag Chemistry for Gene Supply into Particular Cell Sorts. MBio eight, e01860–17 (2017).

67.

van den Berg van Saparoea, H. B., Houben, D., de Jonge, M. I., Jong, W. S. P. & Luirink, J. Show of Recombinant Proteins on Bacterial Outer Membrane Vesicles by Utilizing Protein Ligation. Appl. Environ. Microbiol. 84, e02567–17 (2018).

68.

Zhang, X.-J. et al. Synergistic Enhancement of Enzyme Efficiency and Resilience through Orthogonal Peptide-Protein Chemistry Enabled Multilayer Building. Biomacromolecules 19, 2700–2707 (2018).

69.

Yin, L., Guo, X., Liu, L., Zhang, Y. & Feng, Y. Self-Assembled Multimeric-Enzyme Nanoreactor for Sturdy and Environment friendly Biocatalysis. ACS Biomater. Sci. Eng. four, 2095–2099 (2018).

70.

Jia, L., Minamihata, Okay., Ichinose, H., Tsumoto, Okay. & Kamiya, N. Polymeric SpyCatcher Scaffold Allows Bioconjugation in a Ratio-Controllable Method. Biotechnol. J. 12, 1700195 (2017).

71.

Sutter, M., Greber, B., Aussignargues, C. & Kerfeld, C. A. Meeting rules and construction of a 6.5-MDa bacterial microcompartment shell. Science 356, 1293–1297 (2017).

72.

Bae, Y. et al. Engineering Tunable Twin Purposeful Protein Cage Nanoparticles Utilizing Bacterial Superglue. Biomacromolecules 19, 2896–2904 (2018).

73.

Liu, X. et al. Versatile Engineered Protein Hydrogels Enabling Decoupled Mechanical and Biochemical Tuning for Cell Adhesion and Neurite Progress. ACS Appl. Nano Mater. 1, 1579–1585 (2018).

74.

Banerjee, A. & Howarth, M. Nanoteamwork: covalent protein meeting past duets in the direction of protein ensembles and orchestras. Curr. Opin. Biotechnol. 51, 16–23 (2018).

75.

Fairhead, M. & Howarth, M. Web site-Particular Biotinylation of Purified Proteins Utilizing BirA. Strategies Mol. Biol. 1266, 171–184 (2015).

76.

Guan, Y. et al. An equation to estimate the distinction between theoretically predicted and SDS PAGE-displayed molecular weights for an acidic peptide. Sci. Rep. 5, 13370 (2015).

77.

Aon, J. C. et al. Suppressing Posttranslational Gluconoylation of Heterologous Proteins by Metabolic Engineering of Escherichia coli. Appl. Environ. Microbiol. 74, 950–958 (2008).

78.

Aida, Y. & Pabst, M. J. Elimination of endotoxin from protein options by part separation utilizing Triton X-114. J. Immunol. Strategies 132, 191–5 (1990).

79.

Prepare dinner, I. F. Proof based mostly route of administration of vaccines. Hum. Vaccin. four, 67–73 (2008).

80.

Zhang, L., Wang, W. & Wang, S. Impact of vaccine administration modality on immunogenicity and efficacy. Skilled Rev. Vaccines 14, 1509–1523 (2015).

81.

Moyer, T. J., Zmolek, A. C. & Irvine, D. J. Past antigens and adjuvants: formulating future vaccines. J. Clin. Make investments. 126, 799–808 (2016).

82.

Hutchings, C. L., Gilbert, S. C., Hill, A. V. S. & Moore, A. C. Novel Protein and Poxvirus-Based mostly Vaccine Combos for Simultaneous Induction of Humoral and Cell-Mediated Immunity. J. Immunol. 175, 599–606 (2005).

83.

Goodman, A. L. et al. New Candidate Vaccines in opposition to Blood-Stage Plasmodium falciparum Malaria: Prime-Enhance Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based mostly on Merozoite Floor Protein 1. Infect. Immun. 78, 4601–4612 (2010).


Supply hyperlink
asubhan

wordpress autoblog

amazon autoblog

affiliate autoblog

wordpress web site

web site growth

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close